Rekombinanter SARS-CoV-2 Spike Antikörper (AA 319-541)
Kurzübersicht für Rekombinanter SARS-CoV-2 Spike Antikörper (AA 319-541) (ABIN7581775)
Target
Alle SARS-CoV-2 Spike Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
-
-
Bindungsspezifität
- AA 319-541
-
Expressionssystem
- Phage display
-
Verwendungszweck
- recombinant anti-SARS-CoV-2 spike antibody
-
Spezifität
- This is an antibody developed by antibody phage display technology using a human naive antibody gene library and SARS-CoV-2 antigen. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies.
-
Kreuzreaktivität (Details)
- No known cross reactivity. No cross-reactivity to other human coronaviruses.
-
Produktmerkmale
- This antibody can be detected with anti-mouse Fc secondary antibodies.
-
Aufreinigung
- Protein A purification
-
Immunogen
- No immunization, animal-free antibody development. Antigen: Spike Protein SARS-CoV2 RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF
-
Isotyp
- IgG2a
-
-
-
-
Applikationshinweise
- Western Blot: 0.2-5 μg/mL ELISA: 1-12 μg/mL as coating antibody 0.5-5 μg/mL as detection antibody IF: 0.1 - 10 μg/mL Optimal working dilution should be determined by the investigator
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS, pH 7.4,
-
Lagerung
- -20 °C
-
-
- SARS-CoV-2 Spike
-
Andere Bezeichnung
- SARS-CoV-2 spike protein (RBD)
-
Hintergrund
- Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that could inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.
-
Molekulargewicht
- 76 kDa
-
NCBI Accession
- YP_009724390
-
UniProt
- P0DTC2
Target
-